Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, In...
20374 Seneca Meadows Parkway
Germantown, MD 20876
Founded in 1998
Intrexon Seeks Acquisitions
May 14 15
Intrexon Corporation (NYSE:XON) will consider acquisitions. We continue to track to our ambitious expectations," commented Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon. "As the benefits of our technology platforms and business model accumulate, we expect to continue to drive operating and financial performance in such a way as to produce excellent capital efficiency, which will allow us to grow both organically and by acquisition.
Intrexon Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Results Ended March 31, 2015
May 11 15
Intrexon Corporation announced unaudited consolidated earnings results for the first quarter results ended March 31, 2015. For the quarter, the company reported total revenues of $3,849,000 against $7,854,000 a year ago. Operating loss was $87,123,000 against $17,872,000 a year ago. Income before income taxes was $26,599,000 against $3,555,000 a year ago. Net income attributable to Intrexon was $27,097,000 against $4,115,000 a year ago. Net income per share, diluted was $0.25 against $0.04 a year ago. EBITDA was $31,663,000 against $6,218,000 a year ago. Adjusted LBITDA was $11,309,000 against adjusted EBITDA of $17,585,000 a year ago. Adjusted LBITDA per diluted share was $0.11 against adjusted EBITDA per diluted share of $0.18 a year ago.
Intrexon Declares Special Stock Dividend, Date of Distribution Will Occur in Mid-June 2015
May 11 15
Intrexon’s Board of Directors declared a special stock dividend of 17,830,305 shares of ZIOPHARM common stock owned by Intrexon to its shareholders. The distribution of the special stock dividend will be made on the Distribution Date to all Intrexon shareholders of record on June 4, 2015. The date of distribution by Intrexon of the special stock dividend is contemplated to occur in mid-June 2015.